Basic Information

Common Name
B-hCD47 MC38
Aliases
IAP, MER6, OA3
Catalog Number
310695
Cell Type/ Disease
Colon Carcinoma
Species/ Strain
Mus musculus, C57BL/6
Notice
Biocytogen provides engineering service to generate the humanized tumor cell lines from customer’s own cell lines. Our humanized tumor cell lines are for pharmacology services ONLY.

Target strategy

The exogenous promoter and human CD47 coding sequence was inserted to replace part of murine exon 2 and all of exon 3. The insertion disrupts the endogenous murine Cd47 gene, resulting in a non-functional transcript.

Protein expression analysis

CD47 expression analysis in B-hCD47 MC38 cells by flow cytometry. Single cell suspensions from wild-type MC38 and B-hCD47 MC38 cultures were stained with species-specific anti-CD47 antibody. Human CD47 was detected on the surface of B-hCD47 MC38 cells but not wild-type MC38 cells. The 1-B3 clone of B-hCD47 MC38 cells was used for in vivo experiments.

Tumor growth curve

Subcutaneous homograft tumor growth of B-hCD47 MC38 cells. B-hCD47 MC38 cells (1×106) were subcutaneously implanted into B-hSIRPA/hCD47 mice (female, 7-week-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hCD47 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.

Publications using B-hCD47 mice

  1. Wang Y, Ni H, Zhou S, He K, Gao Y, Wu W, Wu M, Wu Z, Qiu X, Zhou Y, Chen B, Pan D, Huang C, Li M, Bian Y, Yang M, Miao L, Liu J. Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity. Cancer Immunol Immunother. 2020 Aug 6. doi: 10.1007/s00262-020-02679-5. Epub ahead of print. PMID: 32761423.
  2. Wang Y, Pan D, Huang C, Chen B, Li M, Zhou S, Wang L, Wu M, Wang X, Bian Y, Yan J, Liu J, Yang M, Miao L. Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody. MAbs. 2020 Jan-Dec;12(1):1748322. doi: 10.1080/19420862.2020.1748322. PMID: 32275842; PMCID: PMC7153848.